Read by QxMD icon Read

Expert Review of Pharmacoeconomics & Outcomes Research

Francoise F Hamers, Salah Ghabri, Catherine Le Gales
OBJECTIVES: To review the selection and methods used for deriving health state utility (HSU) estimates included in the cost-utility analyses (CUA) submitted by manufacturers to the National Authority for Health (HAS) during the first 2 years after the introduction of the economic evaluation for price setting in France. METHODS: We reviewed all manufacturers' submissions that included a CUA and were assessed by HAS by the end of October 2015 (N=34). We reviewed the identification, selection, and methods used to estimate HSU and compared them with those recommended by HAS...
January 29, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
Usha Sambamoorthi, Drishti Shah, Xiaohui Zhao
Arthritis and depression are two of the top disabling conditions. When arthritis and depression exist in the same individual, they can interact with each other negatively and pose a significant healthcare burden on the patients, their families, payers, healthcare systems, and society as a whole. Areas covered: The primary objective of this review is to summarize, identify knowledge gaps and discuss the challenges in estimating the healthcare burden of depression among individuals with arthritis. Electronic literature searches were performed on PubMed, Embase, EBSCOhost, Scopus, the Cochrane Library, and Google Scholar to identify relevant studies...
January 20, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
J Schepers, J Plaete, I De Bourdeaudhuij, L Annemans, S Simoens
OBJECTIVES: Four hurdles associated with economic evaluations in welfare interventions were identified and discussed in a previous published literature review. These hurdles include (i) 'Ignoring the impact of condition-specific outcomes', (ii) 'Ignoring the impact of QoL externalities', (iii) 'Calculation of costs from a too narrow perspective' and (iv) 'The lack of well-described & standardized interventions'. This study aims to determine how healthcare providers and social workers experience and deal with these hurdles in practice and what solutions or new insights they would suggest...
January 16, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
Issa J Dahabreh, John B Wong, Thomas A Trikalinos
Structural models are mathematical representations of the salient aspects of a phenomenon or process. Models of even moderate complexity are "run" using computer-based numerical analysis and simulation. In medicine, such models are used for inference, prediction, or to inform clinical and policy decision-making; thus, model assessment is paramount. Areas covered: This paper provides a unifying overview of methods for model validation and calibration, and surveys studies comparing alternative validation and calibration approaches...
January 3, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
Sun-Hong Kwon, Sun-Kyeong Park, Ji-Hye Byun, Eui-Kyung Lee
INTRODUCTION: In order to look beyond the cost-effectiveness analysis, this study used a multi-criteria decision analysis (MCDA), which reflects societal values with regard to reimbursement decisions. This study aims to elicit societal preferences of the reimbursement decision criteria for anti cancer drugs from public and healthcare professionals. METHODS: Eight criteria were defined based on a literature review and focus group sessions: disease severity, disease population size, pediatrics targets, unmet needs, innovation, clinical benefits, cost-effectiveness, and budget impacts...
January 3, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
Eun-Sook Kim, Jung-Ae Kim, Eui-Kyung Lee
BACKGROUND: Since the positive-list system was introduced, concerns have been raised over restricting access to new cancer drugs in Korea. Policy changes in the decision-making process, such as risk-sharing agreement and the waiver of pharmacoeconomic data submission, were implemented to improve access to oncology medicines, and other factors are also involved in the reimbursement for cancer drugs. The aim of this study is to investigate the reimbursement listing determinants of new cancer drugs in Korea...
January 3, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
Koen Degeling, Hendrik Koffijberg, Maarten J IJzerman
The ongoing development of genomic medicine and the use of molecular and imaging markers in personalized medicine (PM) has arguably challenged the field of health economic modeling (HEM). This study aims to provide detailed insights into the current status of HEM in PM, in order to identify if and how modeling methods are used to address the challenges described in literature. Areas covered: A review was performed on studies that simulate health economic outcomes for personalized clinical pathways. Decision tree modeling and Markov modeling were the most observed methods...
December 27, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Wei Zhang, Huiying Sun, Daphne Guh, Aslam H Anis
BACKGROUND: In 1998, the province of Ontario, Canada implemented price-cap '70/90' regulations: the first generic must be priced at ≤70% of the associated brand-name price and subsequent generics must be priced at ≤90% of the first generics' price. The price-cap was further lowered to 50% in 2006 and 25% in 2010 for all generic drugs regardless of the first or subsequent generic entrants. This study assessed the impact of such price-cap regulations on market entry by generic firms using the formulary database from 9 provinces (January 2004-March 2013)...
December 27, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Balázs Nagy, Juliana Setyawan, David Coghill, Tamás Soroncz-Szabó, Zoltán Kaló, Jalpa A Doshi
BACKGROUND: Models incorporating long-term outcomes (LTOs) are not available to assess the health economic impact of attention-deficit/hyperactivity disorder (ADHD). OBJECTIVE: Develop a conceptual modelling framework capable of assessing long-term economic impact of ADHD therapies. METHODS: Literature was reviewed; a conceptual structure for the long-term model was outlined with attention to disease characteristics and potential impact of treatment strategies...
December 26, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Michelle Jenks, Matthew Taylor, Judith Shore
BACKGROUND: An evaluation was conducted to estimate the cost-effectiveness of insufflation of warmed humidified CO2 during open and laparoscopic colorectal surgery compared with usual care from a UK NHS perspective. METHODS: Decision analytic models were developed for open and laparoscopic surgery. Incremental costs per quality-adjusted life year (QALY) were estimated. The open surgery model used data on the incidence of intra-operative hypothermia and applied risks of complications for hypothermia and normothermia...
December 26, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Tracy L Skaer, Winghan Jacqueline Kwong
Fibromyalgia (FM) is a chronic syndrome that usually develops midlife. It is associated with a high burden of illness that causes significant disability. Areas covered: Diagnosis can be challenging, given the diverse clinical presentation among those with FM. Therefore, the typical health care journey for a patient with FM is lengthy and complex. There is no acknowledged treatment algorithm for FM, prescribing patterns vary markedly, and patients are likely to receive suboptimal or inappropriate pharmacotherapy...
December 20, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Tomasz Bochenek, Ewa Kocot, Marcin Rodzinka, Brian Godman, Katarzyna Maciejewska, Susan Kamal, Andrzej Pilc
BACKGROUND: The appropriate access to public information is very important for healthcare system stakeholders. The goal of this study was to examine how the execution of the formally existing right to public information on the HTA-based recommendations on reimbursement of new health technologies from public funds has been changing in Poland. METHODS: All recommendations published within two predefined equal periods of time between 2013 and 2015 were analyzed. The gathered data was subjected to statistical analysis...
December 5, 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Kelly Fust, Anju Parthan, Michael Maschio, Qing Gu, Xiaoyan Li, Gary H Lyman, Spiros Tzivelekis, Guillermo Villa, Milton C Weinstein
We reviewed the evolution of the methods used in cost-effectiveness analyses of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary prevention of febrile neutropenia (FN) in patients receiving myelosuppressive cancer chemotherapy. Areas covered: FN is a side effect of myelosuppressive chemotherapy associated with significant morbidity, mortality, and costs. The risk of FN may depend on the drugs used within a chemotherapy regimen, and an FN event may cause chemotherapy dose reductions or delays in subsequent cycles...
February 2017: Expert Review of Pharmacoeconomics & Outcomes Research
Mondher Toumi, Ekkehard Beck, Steve Sherman, Leyla Mohseninejad, Samuel Aballéa
No abstract text is available yet for this article.
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Adam L Gordois, Peter P Toth, Ruben Gw Quek, Emma M Proudfoot, Carly J Paoli, Shravanthi R Gandra
People with cardiovascular disease (CVD) often require time off work to recover from illness or surgery; for example, following a myocardial infarction (MI) or stroke. These individuals incur income losses, work-related productivity is reduced for employers, and output is reduced for the wider economy. Productivity impacts to the economy also arise due to CVD-related mortality. Areas covered: A systematic literature review was conducted to identify and collate studies that report the magnitude of work-related productivity losses associated with CVD generally or specific cardiovascular (CV) events or conditions (coronary heart disease, MI, stroke, transient ischemic attack, angina, heart failure, peripheral artery disease, coronary revascularization)...
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
J Jaime Caro, Jörgen Möller
No abstract text is available yet for this article.
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Simon B Zeichner, Christine G Kohn, Daniel A Goldstein
Despite its FDA approval and incorporation into the National Comprehensive Cancer Network (NCCN) treatment guidelines, ramucirumab (RAM) is associated with a drug acquisition cost that is substantially higher than other approved options. Given its substantial cost, the presence of a viable alternative treatment option, and its minimal survival improvement, the usefulness of RAM in clinical practice has been called into question. Areas covered: In this paper, we outline the cost, benefits, and economic implications of RAM from a US perspective, as it is used in the treatment of mCRC...
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
A Malet-Larrea, V García-Cárdenas, L Sáez-Benito, S I Benrimoj, B Calvo, E Goyenechea
The aim was to determine whether professional pharmacy services (PPS) provided to ambulatory patients attending community pharmacy are cost-effective compared with usual care (UC). Areas covered: MEDLINE, Web of Knowledge, Scopus, Cochrane Library and Centre for Reviews and Dissemination databases were searched, and the risk of bias of randomized controlled trials, and the methodological quality of economic evaluations was assessed. A total of 17 economic evaluations of 13 studies were included. Seven studies were classified as high-, three as medium- and three as low-quality...
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Ghislaine A P G van Mastrigt, Mickaël Hiligsmann, Jacobus J C Arts, Pieter H Broos, Jos Kleijnen, Silvia M A A Evers, Marian H J M Majoie
Systematic reviews of economic evaluations are useful for synthesizing economic evidence about health interventions and for informing evidence-based decisions. Areas covered: As there is no detailed description of the methods for performing a systematic review of economic evidence, this paper aims to provide an overview of state-of-the-art methodology. This is laid out in a 5-step approach, as follows: step 1) initiating a systematic review; step 2) identifying (full) economic evaluations; step 3) data extraction, risk of bias and transferability assessment; step 4) reporting results; step 5) discussion and interpretation of findings...
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
F W Thielen, Gapg Van Mastrigt, L T Burgers, W M Bramer, Hjm Majoie, Smaa Evers, J Kleijnen
This article is part of the series "How to prepare a systematic review of economic evaluations (EES) for informing evidence-based healthcare decisions", in which a five-step approach is proposed. Areas covered: This paper focuses on the selection of relevant databases and developing a search strategy for detecting EEs, as well as on how to perform the search and how to extract relevant data from retrieved records. Expert commentary: Thus far, little has been published on how to conduct systematic review EEs...
December 2016: Expert Review of Pharmacoeconomics & Outcomes Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"